Introduction
Prophylactic treatment with anticoagulants and antiplatelet agents has clear benefits in select patients with cardiac and vascular diseases [1, 2] . Over the previous decade, there has been a significant increase in the use of these agents for primary prevention of stroke and heart disease and for prophylaxis and after percutaneous cardiac interventions. Patients experiencing intracranial hemorrhage (ICH) while fully anticoagulated have been reported to present with larger hematoma volumes and suffer a worse prognosis compared to control groups with normal coagulation profiles [3] [4] [5] .
Further study has demonstrated that ICH progression in anticoagulated patients could be halted, and mortality significantly reduced, with a prompt reversal of anticoagulation [6] .
Some investigators have also reported that a prehospital antiplatelet regimen may be associated with hematoma expansion, an increased mortality rate, and a poor functional outcome [7] [8] [9] [10] . As such, many institutions have established protocols to "reverse" the impairment of platelet aggregation caused by antiplatelet agents in patients presenting with ICH.
Several antiplatelet agents are commonly used in the outpatient setting. Aspirin is widely used for a variety of indications including risk reduction from transient ischemic attacks, prevention of primary myocardial infarction, and prevention of colorectal cancer [11] . Aspirin irreversibly binds to the cyclooxygenase-1 (COX-1) enzyme and subsequently inhibits production of thromboxane A2, a potent eicosanoid involved in platelet aggregation [12] . Non-steroidal anti-inflammatory drugs (NSAIDs) are typically used for relief from arthritis and headache pain. This class of medications acts upon on COX-1 in a reversible, dose-dependent inhibition; as the drug concentration decreases, COX-1 regains its enzymatic activity. Aspirin differs from NSAIDs functionally in that aspirin-induced COX-1 inhibition is irreversible, secondary to protein acetylation [13] .
Clopidogrel and ticlopidine both selectively and irreversibly inhibit the P2Y 12 ADP receptor. These agents have been used effectively to treat a wide range of cardiovascular and cerebrovascular diseases, such as for prophylaxis after coronary or intracranial stent placement. Due to an active metabolite, clopidogrel in particular persists after cessation of the medication. Some studies have demonstrated a higher incidence of post-operative bleeding with clopidogrel as compared to aspirin, prompting some experts to recommend aggressive anti-platelet reversal for up to 4 days after the last known dose [14] . This review will focus on the treatment of ICH in patients taking prehospital NSAIDS, aspirin and clopidogrel (Plavix), and ticlopidine (Ticlid). Given the heterogeneity of the etiology of intracranial hemorrhages, spontaneous ICH and traumatic hemorrhages will be reviewed separately. The pertinent literature is evaluated and reviewed for evidence-based recommendations or guidelines to provide treatment guidance to clinicians for patients presenting with antiplatelet associated intracranial hemorrhages.
Methods

Literature Review
PUBMED and MEDLINE databases were searched for publications from 1966 to the present using MeSH terms 'antiplatelet', 'aspirin', 'clopidogrel (Plavix)', 'ticlopidine (Ticlid)', 'intracranial hemorrhage', 'head injury', 'traumatic hemorrhage', 'subdural hematoma', and 'stroke'. The search was limited to articles in the English language and those relating to human subjects over the age of 18. Reference sections of recent articles, guidelines and reviews were reviewed and pertinent articles identified. Initially, articles identified as relevant were retrieved in abstract format. Full-text manuscripts were subsequently obtained for all original articles applicable to the current review.
Two authors independently evaluated all selected articles (PC, AS). For each study, study design (prospective or retrospective, use of control group, randomization), number of patients included and outcomes of the study were recorded. These results were used to assess if any evidence-based recommendations were able to be made from the literature.
Spontaneous ICH
Spontaneous intracerebral hemorrhage constitutes 10 % to 15% of all strokes and is a devastating stroke subtype. Clinical trials of surgical interventions have failed to demonstrate a consistent benefit [15] . Many predictors of negative outcome have been consistently described in patients suffering from spontaneous ICH, including oral anticoagulant therapy [3, 5] . Futhermore, warfarin use has been associated with larger volumes of ICH on baseline imaging, subsequent ICH growth, and increased mortality [16, 17] . Since hemorrhage expansion is an independent predictor of mortality and poor functional outcome, established guidelines require the prompt reversal of warfarininduced effects [18] .
Effects on Outcome in Spontaneous ICH
Whether or not antiplatelet medication use at the time of spontaneous ICH influences hemorrhage expansion and neurologic outcome is controversial. Several studies with various designs, sizes, and exclusion criteria have displayed conflicting results (Table 1) [7, 9, 10, [19] [20] [21] [22] [23] . While these studies typically report the use of any antiplatelets together in one research arm, aspirin users account for the vast majority of the subpopulation in all studies. The efficacy of platelet transfusion as it relates to outcome was specifically assessed in only one study, but often not in the remainder, thus . In a phase II trial of rFVIIa for acute ICH, treatment with the recombinant factor and a longer time from onset to baseline CT were related to a decrease in hemorrhage growth in five models of ICH growth; four of the five models found no relationship between antiplatelet use and ICH growth [25] . In these studies, no transfusion of platelets was provided to study participants. Within these studies, at least 80% of the antiplatelet groups were taking ASA alone. The effect of antiplatelet use on outcomes in other prospective and retrospective analyses ranges from non-significant to a 2.7-fold increased 30 day mortality rate and a 7.6-fold increase in hematoma enlargement [7, 9, 10, [19] [20] [21] [22] [23] .
No study specifically addresses the effects of P2Y 12 ADP receptor inhibitors on spontaneous ICH. When a specific agent was specified by the study, clopidogrel and ticlopidine were being taken by 0 to 35.1% of the patients in the antiplatelet arms of studies in the literature [7, 9, 10, [19] [20] [21] [22] [23] . Toyoda et al. [10] reported on a series of 251 total patients with 57 antiplatelet users prior to spontaneous ICH. Ticlopidine was used secondary to the lack of availability of clopidogrel in Japan at the time. Twelve patients were on ticlopidine alone and 8 were taking a combination of ticlopidine and another antiplatelet (35.1%). In this series, the use of prehospital antiplatelet agents was an independent predictor for hematoma enlargement (p<0.01), emergent evacuation (p=0.021) and emergent death [10] .
Reversal of Antiplatelet Agents in Spontaneous ICH
In the setting of a spontaneous intracranial hemorrhage, attempts to "reverse" 
Traumatic ICH
Traumatic brain injury (TBI) is responsible for more than one million hospital visits, roughly 200,000 hospital admissions, and 50,000 deaths in the United States annually [33] . Given the considerable increase in the use of antiplatelet agents for stroke prevention and cardiac prophylaxis, many patients taking antiplatelet agents will subsequently experience intracranial hemorrhage secondary to TBI. In an attempt to reduce the increased morbidity and mortality associated with TBI in patients on antiplatelet or anticoagulant medications, some centers frequently reverse the effects of antiplatelet agents with platelet transfusion. In a study of anticoagulated patients with traumatic ICH, rapid warfarin reversal led to a reduction in hemorrhage progression and a decrease in mortality (p < 0.001) [6] . However, the reversal of platelet dysfunction in patients with TBI on antiplatelet medications has not been fully investigated and no guidelines currently exist regarding this practice.
Effects on Outcome in Traumatic ICH
The current review includes 1 prospective and 10 retrospective studies that have evaluated the outcomes associated with prehospital antiplatelet use in patients admitted for traumatic head injuries (Table 2) 
Reversal of Antiplatelets in Traumatic ICH
Based on the majority of the studies available, it is conceivable that preinjury antiplatelet therapy may convert a minor traumatic ICH into a progressive ICH [11] .
However, currently available studies do not offer recommendations to clinicians on the use of reversal agents for patients with TBI on preinjury antiplatelet therapy. One study assessed patients who received platelet transfusions compared with those who did not to assess outcome differences in the setting of traumatic ICH [43] . In this multi-center retrospective series, 166 patients with traumatic ICH received platelet transfusions, and 162 did not. The mortality rate for the transfused patients was 17.5%, while mortality for those who did not receive platelet transfusions was 16.7% (p=0.85) [43] . Unfortunately, statistical analysis was not reported for any specific anti-platelet agent. Hence, though at first glance it may seem that, as with warfarin, reversal of antiplatelet effects with platelet transfusion should lead to a reduction in mortality and morbidity in the setting of a traumatic ICH, the only study that assessed this hypothesis did not find evidence to support this practice.
Options for Reversal
The literature regarding "reversal" of prehospital aspirin therapy after acute intracranial hemorrhage is equivocal. At many institutions, it is standard practice to recommend platelet transfusion in the setting of intracranial hemorrhage in an effort to stem the salicylate effect upon platelet aggregation [44] . Although there is no specific antidote, the aspirin effect is believed to be reversed by one platelet transfusion (1 single donor or 5 pooled concentrates) [26, 45] . Furthermore, other agents for reversal of the aspirin effect have received basic investigation. Desmopressin seems capable of correcting aspirin-induced platelet dysfunction, although large clinical studies describing relevant outcome parameters have not been undertaken [46] [47] [48] . Altman, et al. [49] treated healthy volunteers with aspirin and found that recombinant factor VIIa (rFVIIIa) combined with other agonists was able to reverse the anti-aggregating effect of aspirin.
No randomized study has been reported outcomes of acute ICH with reference to the reversal the aspirin effect.
Clopidogrel belongs to the class of thienopyridine derivatives, which act by blocking the ADP receptor on the platelet. Like aspirin, no specific antidote exists for the reversal of these agents. In an ex vivo study on healthy volunteers given aspirin and clopidogrel, a platelet transfusion consisting of 10 to 12.5 concentrate units successfully restored platelet reactivity [45] . However, given that an active metabolite of clopidogrel persists after cessation of the medication, some experts recommend continued platelet transfusion 4 or 5 days after the last dose of the medication [44] . In another ex vivo study of healthy volunteers treated with aspirin plus clopidogrel, rFVIIa reversed the inhibitory platelet effects of these agents [49] . While the clinical utility of desmopressin has not been assessed in the ICH population, Ranucci, et al. [50] reported the antiplatelet effects of clopidogrel and aspirin were partially reversed by an intravenous infusion of desmopressin after carotid endarterectomy. No randomized studies have been reported to assess outcomes after the reversal of thienopyridines in the setting of acute ICH. 
Proposed Protocol for Reversal of Antiplatelets
Discussion
Effect of pharmacokinetics
There is a known substantial variation in patient response to antiplatelet medications [51] . This diversification of molecular effectiveness amongst patients may, in part, explain some of the conflicting outcome results seen in the retrospective reviews presented in Table 1 and Table 2 . Recently, Naidech et al. [52] [53] [54] reported several studies linking objective measures of platelet function with increased mortality, increased early clot growth, worse functional outcomes at 3 months and intraventricular extension after ICH. These authors used two bedside optical detection systems which measured platelet induced aggregation inhibition due to aspirin and clopidogrel. They determined that abnormal platelet activity results, not the reported use of antiplatelet medications were associated with these negative outcomes and posited that increasing platelet activity may be a more appropriate potential target to improve outcomes after ICH [53] . While more studies at various centers are needed to confirm these findings, these studies provide early evidence that restoring the platelet activity in specifically targeted patients directly upon admission may be of benefit.
Next-generation Antiplatelet Agents
Potent metabolites of the thienopyridines (clopidogrel and ticlopidine) irreversibly inhibit the P2Y 12 receptor. Thus, urgent surgical intervention in patients taking these agents is often problematic. From the cardiac literature, clopidogrel treatment within 4-5 days of a coronary artery bypass grafting procedures has been associated with increased blood loss, reoperation for bleeding, increased transfusion requirements, and prolonged intensive care unit and hospital stays [14, 29, 55] . As emergent surgery is often a necessity in the setting of acute coronary syndrome, two direct and reversible P2Y 12 antagonists with rapid onset of action have been developed. These new agents, which are currently in Phase III trials, are attractive alternatives to the thienopyridines, especially in situations whereby the rapid inhibition of platelet aggregation or its quick reversal are required [56] . Thus, with the addition of these new P2Y 12 inhibitors, physicians will be able to prescribe a more patient-specific antiplatelet regimen based upon individual riskbenefit analysis.
Summary of Findings
The data assessing the relationship between outcomes and prehospital antiplatelet agents in the setting of ICH is contradictory in both the trauma and the stroke literature.
The majority of studies reveal a worsened outcome in ICH after taking ASA. After clopidogrel ingestion both dedicated studies in the trauma literature noted worse outcomes, while the study including the highest percentage of patients taking thienopyridines in the spontaneous ICH literature noted worse outcomes as well when compared to controls [10, 39, 40] . Only one retrospective review assessed outcomes after platelet transfusion, the mainstay of antiplatelet reversal at many institutions. Currently, a randomized trial is recruiting patients in order to determine whether platelet transfusion ameliorates hematoma enlargement in the setting of acute ICH [7] . At present, the literature contains insufficient information to establish any guidelines or treatment recommendations. In light of this, the current authors have proposed a protocol for antiplatelet reversal in both spontaneous and traumatic acute ICH.
